Skip to search formSkip to main contentSkip to account menu

Tumor Regression Grade

A pathologic grading system used to evaluate the tumor response to preoperative chemotherapy and radiation.
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2017
2017
Pathological response of colorectal liver metastases treated after induction treatment.
BACKGROUND Mortality for colorectal cancer is mainly due to liver metastases, surgical resection remains the curative treatment… 
2017
2017
Is there a relation between the changes in circulating lymphocyte counts due to neoadjuvant chemoradiotherapy and intratumoral lymphocytic response and tumor regression grade in locally advanced…
There are controversies about the relation between the peripheral lymphocyte levels and response to neoadjuvant therapy. While… 
2017
2017
“ TUMOR REGRESSION GRADE AFTER NEOADJUVANT CHEMORADI ATION AND SURGERY IN LOW RECTAL CANCER
Background: The role of Mandard’s Tumor Regression Grade (TRG) classification is still controversial to define prognostic role of… 
2015
2015
Is Pathologic Near-Total Regression an Appropriate Indicator of a Good Response to Preoperative Chemoradiotherapy Based on Oncologic Outcome of Disease?
AbstractWe evaluated the oncologic outcomes of patients with rectal cancer who demonstrated pathologic near-total regression (NTR… 
Review
2013
Review
2013
Rates of pathologic complete or near complete response following neoadjuvant chemotherapy and stereotactic body radiation therapy for borderline resectable pancreatic cancer.
221 Background: While the clinical response from induction chemotherapy followed by stereotactic body radiation therapy (SBRT… 
2012
2012
Diffusion-weighted MR volumetry for assessing the response of rectal cancer to combined radiation therapy with chemotherapy.
Editor: In the study by Curvo-Semedo and colleagues (1), which appeared in the September 2011 issue of Radiology, the utility of… 
2012
2012
Abstract LB-219: Neoadjuvant multidisciplinary phase II study (BRANCH) of an early bevacizumab schedule plus chemo-radiation therapy in rectal cancer: efficacy, safety, and biomarkers.
Proceedings: AACR 103rd Annual Meeting 2012‐‐ Mar 31‐Apr 4, 2012; Chicago, IL BACKGROUND: The benefits of combining bevacizumab… 
2010
2010
Plasma levels of total RNA and hTERT mRNA as biomarkers of response in rectal cancer patients receiving preoperative chemoradiotherapy.
3648 Background: The levels of telomere-specific reverse transcriptase (hTERT) transcripts have been found to be a marker of… 
2010
2010
KRAS mutation status and clinical outcome of preoperative chemoradiation (CRT) with or without cetuximab in locally advanced rectal cancer (LARC): A pooled analysis of two phase II trials.
3650 Background: Cetuximab-containing chemotherapy is known to be active for KRAS wild type (KRAS- wt) metastatic colorectal… 
2005
2005
Correlation between FDG-PET and pathologic response in patients with rectal cancer treated with neoadjuvant chemo-radiotherapy: First results of the Bologna Project
3623 Background: The aim of the study was to evaluate the predictive value of FDG-PET in patients (pts) treated with neoadjuvant… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)